School Reintegration for Childhood and Adolescent Cancer Survivors
Are you a healthcare professional experienced in working with childhood cancer survivors?
Researchers at BC Cancer and BC Children’s Hospital are conducting two studies examining barriers and facilitators to re-integration back to school and appropriate educational supports that allow childhood and adolescent cancer survivors to reach their full potential. We would love to hear your insights!
Studies:
- Educational Outcomes in Childhood and Adolescent Survivors of Hematologic Malignancies (CAHM)
Principal Investigator: Dr. Stuart Peacock, DPhil, SFU, BC Cancer - Healthcare Providers and Educators role in school re-integration for Childhood and Adolescent Neuro-Oncology Survivors (CANO)
Principal Investigator: Dr. Meera Rayar, MD, BC Children’s Hospital
If you:
- Are a service provider (e.g., healthcare professional, social worker, psychologist, counselor, child life specialist, etc.);
- Have experience working with childhood and adolescence cancer survivors;
- Provide services in British Columbia
we would love to hear from you.
The study will involve a 30 to 60-minute one-on-one online interview and will take place from March 2025 to June 2025.
For more information, please visit our website: https://www.bccrc.ca/dept/ccr/projects/healthcare-providers-and-educators-role-school-re-integration-childhood-and-adolescent
OR Contact Dr. Sara Izadi-Najafabadi at sizadi@bccrc.ca
STUDY: Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors (Alliance for Clinical Trials in Oncology)
This randomized phase III trial compares standard-dose combination chemotherapy to high-dose combination chemotherapy with stem cell transplant to treat patients with refractory or relapsed germ cell tumours.
- Age Eligibility: 14 years and over
- NOL Date: Canadian NOL June 1, 2016
- Cooperative Group: Alliance for Clinical Trials in Oncology, sponsored in Canada by C17 for pediatric centres
- NCT02375204, Alliance Protocol A031102
- https://clinicaltrials.gov/ct2/show/NCT02375204
